Randomised controlled trial of a calcium channel or angiotensin converting enzyme inhibitor/angiotensin receptor blocker regime to reduce blood pressure variability following ischaemic stroke (CAARBS): A protocol for a feasibility study

Robinson, Thompson G., Davison, William J., Rothwell, Peter M. and Potter, John F. (2019) Randomised controlled trial of a calcium channel or angiotensin converting enzyme inhibitor/angiotensin receptor blocker regime to reduce blood pressure variability following ischaemic stroke (CAARBS): A protocol for a feasibility study. BMJ Open, 9 (2). ISSN 2044-6055

Preview	PDF (Accepted manuscript) - Accepted Version Available under License Creative Commons Attribution. Download (768kB) | Preview
Preview	PDF (Published_Version) - Published Version Available under License Creative Commons Attribution. Download (690kB) | Preview

Abstract

Introduction: Raised blood pressure (BP) is common after stroke and is associated with a poor prognosis, yet trials of BP lowering in the immediate poststroke period have not demonstrated a benefit. One possible explanation for this may be that BP variability (BPV) rather than absolute levels predicts outcome, as BPV is increased after stroke and is associated with poor outcomes. Furthermore, there is evidence of distinct antihypertensive class effects on BPV despite similar BP-lowering effects. However, whether BPV in the immediate poststroke period is a therapeutic target has not been prospectively investigated. The objectives of this trial are to assess the feasibility and safety of recruiting patients following an acute ischaemic stroke or transient ischaemic attack (TIA) to an interventional randomised controlled trial comparing the effects of two different antihypertensive drug classes on BPV. Secondary exploratory objectives are to assess if different therapeutic strategies have diverse effects on levels of BPV and if this has an impact on outcomes.  Methods: 150 adult patients with first-ever ischaemic stroke or TIA who require antihypertensive therapy for secondary prevention will be recruited within 7 days of the event from stroke services across three sites. After baseline assessments they will be randomly assigned to treatment with a calcium channel blocker or ACE inhibitor/angiotensin receptor blocker-based regimen and followed up for a period of three months.  Ethics and dissemination: Ethical and regulatory approvals have been granted. Dissemination is planned via publication in peer-reviewed medical journals and presentation at relevant conferences.  Trial registration number: ISRCTN10853487.

Item Type:	Article
Uncontrolled Keywords:	blood pressure,blood pressure variability,cerebrovascular disease,stroke,medicine(all) ,/dk/atira/pure/subjectarea/asjc/2700
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Related URLs:	http://www.scopus.com/inward/record.url?... https://bmjopen.bmj.com/content/9/2/e025...
Depositing User:	LivePure Connector
Date Deposited:	14 Nov 2018 11:31
Last Modified:	22 Oct 2022 04:16
URI:	https://ueaeprints.uea.ac.uk/id/eprint/68887
DOI:	10.1136/bmjopen-2018-025301

Downloads

Actions (login required)

View Item